Regulatory bottleneck is thwarting biologicals, says Biotalys CEO: ‘We’ve got to figure out another way’
“Put it this way,” says Kevin Helash. “If you’re trying to fund an eight-year regulatory process with investors who have a window of five years, there’s a disconnect there.”